Prostate-specific Antigen at 3 Months As a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database

Mario Hassi Roman, Kinga Mate,Pedro De Pablos-Rodriguez, Alvaro Zamora Horcajada, Ana Guijarro Cascales, Angeles Sanchis Bonet,Antoni Vilaseca, Dario Vazquez-Martul Pazos,Estefania Linares Espinos,Jesus Munoz Rodriguez, Jose Manuel de la Morena Gallego, Jose Ramon Aleman,Juan Gomez Rivas,Luigi Formisano,Maria J. Juan Fita, Marc Costa Planells,Mario Dominguez Esteban,Meritxell Perez Marquez, Miguel Garcia Sanz, Nagore Garcia Exposito,Natalia Picola, Pol Servian Vives,Raquel Sopen Sutil,Miguel A. Climent Duran,Miguel Ramirez Backhaus

EUROPEAN UROLOGY OPEN SCIENCE（2024）

Cited 0|Views5

Key words

Prostate cancer,Metastatic hormone-sensitive prostate cancer,Apalutamide,Prostate-specific antigen,Response,Ultrasensitive assay

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined